Bristol Myers Squibb (BMY) Capital Expenditures (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Capital Expenditures for 18 consecutive years, with $305.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Capital Expenditures fell 15.51% year-over-year to $305.0 million in Q2 2026; TTM through Jun 2026 was $1.3 billion, a 1.44% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 5.05% from the prior year.
• Capital Expenditures was $305.0 million for Q2 2026 at Bristol Myers Squibb, down from $347.0 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $378.0 million in Q4 2024 and troughed at $247.0 million in Q3 2022.
• A 5-year average of $307.7 million and a median of $312.5 million in 2025 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures soared 46.24% in 2022 and retreated 15.51% in 2026, its largest moves.
• Over 5 years, Capital Expenditures stood at $346.0 million in 2022, then retreated by 4.62% to $330.0 million in 2023, then grew by 14.55% to $378.0 million in 2024, then dropped by 2.12% to $370.0 million in 2025, then declined by 17.57% to $305.0 million in 2026.
• The last three Capital Expenditures figures came in at $305.0 million (Q2 2026), $347.0 million (Q1 2026), and $370.0 million (Q4 2025), per Business Quant data.